Clinical trial registry record

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 9, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03479372
Last registry update
July 9, 2019
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
PanOptica, Inc.
Enrollment
51
Countries
United States, Czechia, Hungary, Latvia, United Kingdom
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
51
Population
ALL · 50 Years
Duration
2018-04-26 to 2019-06-27
Intervention
PAN-90806 Ophthalmic Suspension
Comparator
Not reported
Outcomes measured
Number of participants with treatment-related adverse events — up to 12 weeks; Mean change from baseline in study eye ETDRS Visual Acuity — through Week 12; Mean change from baseline in study eye retinal thickness — through Week 12; Number of patients needing additional treatment with ranibizumab — through Week 12
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON